{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001386","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.127218+00:00","generated_at":"2026-05-16T11:14:16.064129+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ADC Therapeutics reports preliminary 2025 revenue of ~$73M; cash runway extended to 2028","bullets":["Preliminary Q4 2025 ZYNLONTA net product revenue ~$22M; full year 2025 ~$73M vs $69.3M in 2024.","Cash and cash equivalents ~$261M as of Dec 31, 2025; expected cash runway at least to 2028.","LOTIS-7 Phase 1b shows 89.8% ORR and 77.6% CR; enrollment completion expected H1 2026.","LOTIS-5 Phase 3 topline data expected in Q2 2026; potential sBLA and approval mid-2027 if positive.","IND-enabling activities completed for PSMA-targeting ADC; partnership opportunities being explored."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001386","json":"https://secwatch.observer/filing/0001628280-26-001386.json","markdown":"https://secwatch.observer/filing/0001628280-26-001386.md","text":"https://secwatch.observer/filing/0001628280-26-001386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026001386/0001628280-26-001386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026001386/adc-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:14:16.064129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}